BioNTech shares in focus as lung cancer drug shows survival gain
Clinical data showed BioNTech's lung cancer treatment achieved median overall survival of 18.5 months versus 10.0 months with docetaxel. Berenberg reportedly raised its price target to $140 from $132 on September 16 and maintained a buy rating. BioNTech closed Friday at €86.55 with a market capitalization of €21.42 billion.
BioNTech is often still viewed mainly through its pandemic vaccine success, but the article argues that this overlooks its shift toward oncology. The lung cancer data showed median overall survival of 18.5 months, compared with 10.0 months for docetaxel, while an approval-relevant phase 2 trial continues.
Berenberg reportedly lifted its price target to $140 from $132 on September 16 and kept a buy rating. BioNTech ended Friday at €86.55, giving it a market capitalization of €21.42 billion, a valuation the article says may not fully reflect pipeline progress.
Patients with hard-to-treat lung cancer could benefit if the survival gain holds in further trials and regulators accept it. Investors and employees may see BioNTech's oncology transition shape its prospects, while healthcare systems could face new treatment costs and choices. The data may also influence how the public views biotech beyond vaccines, though late-stage failures remain possible.